Assertio (ASRT) Q2 2024 earnings summary

Executive summary

• Leadership transition completed with a new CEO focused on growth through asset acquisition and integration.

• ROLVEDON established as the primary growth driver, with strong demand and positive market feedback, contributing $15.1 million in Q2 2024 sales.

• Indocin managed effectively despite generic competition, but sales dropped to $6.9 million in Q2 2024, maintaining market share at internal targets.

• Portfolio review ongoing to optimize growth or cash flow from existing assets.

• The company continues to face legal and regulatory challenges, including ongoing opioid-related litigation and shareholder lawsuits.

Financial highlights

• Q2 2024 total product sales were $30.7 million, down from $31.9 million in Q1 and $41.0 million in Q2 2023, reflecting a significant decline in Indocin sales and a shift in product mix.

• ROLVEDON sales rose to $15.1 million from $14.5 million sequentially; Indocin sales fell to $6.9 million from $8.7 million.

• Reported gross margin was 71% (up from 65% in Q1); adjusted gross margin was 73% (down from 78% in Q1) due to inventory write-downs.

• Adjusted EBITDA was $5 million, down from $7.4 million in Q1, mainly due to lower sales and higher inventory write-downs.

• Cash and short-term investments at quarter-end were $88.4 million, up from $80.7 million; debt remained at $40 million.

Outlook and guidance

• 2024 guidance maintained: net product sales of $110–$125 million and adjusted EBITDA of $20–$30 million.

• Guidance may be revisited in November after nine months of results.

• ROLVEDON expected to remain a growth asset through 2025 and beyond, though growth may not be linear each quarter.

• Indocin sales are expected to continue declining due to ongoing and future generic competition.

• Cost of sales as a percentage of revenue is projected to be higher for the remainder of 2024 due to product mix changes.